Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma

Rajkumar Venkatramani, Larry Wang, Jemily Malvar, Dennis Dias, Richard Sposto, Marcio Malogolowkin, Leo Mascarenhas

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Tumor response to chemotherapy has been shown to predict outcome in children with acute lymphoblastic leukemia, osteosarcoma, and Ewing Sarcoma. We evaluated whether tumor necrosis following neo-adjuvant chemotherapy is prognostic for survival in hepatoblastoma (HB). Procedure: Primary tumors from children with newly diagnosed stage III and IV HB who underwent surgical resection following neo-adjuvant chemotherapy were evaluated histologically for the extent of tumor necrosis (total diameter of necrotic and fibrotic tissue divided by total diameter of tumor). Clinical features, laboratory values, pathological features, treatment delivered, and vital status were recorded. Univariate and multivariate Cox regression analyses were performed to evaluate prognostic factors. Results: Thirty-two patients were evaluable. After a median of four cycles of neo-adjuvant chemotherapy gross total surgical resection was achieved in 29 patients and complete resection documented by histology in 22 patients. Three-year event free survival (EFS) and overall survival (OS) of the evaluable patients were 70.3±8.3% and 76.8±7.6%, respectively. Extent of tumor necrosis, platelet count at diagnosis, decline in serum alpha fetoprotein, and surgical margin status (positive vs. negative) were statistically significant predictors for both EFS and OS by univariate analysis. Multivariate analyses revealed that extent of tumor necrosis and surgical margin status predicted improved EFS (P<0.001) and OS (P<0.0001). Conclusions: Extent of tumor necrosis following neo-adjuvant chemotherapy is an independent prognostic factor in patients with newly diagnosed HB. Histological response may potentially be used in strategies to modify post-surgical therapy to improve survival in HB.

Original languageEnglish (US)
Pages (from-to)493-498
Number of pages6
JournalPediatric Blood and Cancer
Volume59
Issue number3
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Hepatoblastoma
Adjuvant Chemotherapy
Necrosis
Survival
Neoplasms
Disease-Free Survival
Ewing's Sarcoma
alpha-Fetoproteins
Osteosarcoma
Survival Analysis
Platelet Count
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Histology
Multivariate Analysis
Regression Analysis
Drug Therapy

Keywords

  • Alpha-fetoprotein
  • Chemotherapy
  • Hepatoblastoma
  • Necrosis
  • Platelet count
  • Surgery

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma. / Venkatramani, Rajkumar; Wang, Larry; Malvar, Jemily; Dias, Dennis; Sposto, Richard; Malogolowkin, Marcio; Mascarenhas, Leo.

In: Pediatric Blood and Cancer, Vol. 59, No. 3, 01.09.2012, p. 493-498.

Research output: Contribution to journalArticle

Venkatramani, R, Wang, L, Malvar, J, Dias, D, Sposto, R, Malogolowkin, M & Mascarenhas, L 2012, 'Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma', Pediatric Blood and Cancer, vol. 59, no. 3, pp. 493-498. https://doi.org/10.1002/pbc.24038
Venkatramani, Rajkumar ; Wang, Larry ; Malvar, Jemily ; Dias, Dennis ; Sposto, Richard ; Malogolowkin, Marcio ; Mascarenhas, Leo. / Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma. In: Pediatric Blood and Cancer. 2012 ; Vol. 59, No. 3. pp. 493-498.
@article{f29843be49a94a2393d3f8656942b6eb,
title = "Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma",
abstract = "Background: Tumor response to chemotherapy has been shown to predict outcome in children with acute lymphoblastic leukemia, osteosarcoma, and Ewing Sarcoma. We evaluated whether tumor necrosis following neo-adjuvant chemotherapy is prognostic for survival in hepatoblastoma (HB). Procedure: Primary tumors from children with newly diagnosed stage III and IV HB who underwent surgical resection following neo-adjuvant chemotherapy were evaluated histologically for the extent of tumor necrosis (total diameter of necrotic and fibrotic tissue divided by total diameter of tumor). Clinical features, laboratory values, pathological features, treatment delivered, and vital status were recorded. Univariate and multivariate Cox regression analyses were performed to evaluate prognostic factors. Results: Thirty-two patients were evaluable. After a median of four cycles of neo-adjuvant chemotherapy gross total surgical resection was achieved in 29 patients and complete resection documented by histology in 22 patients. Three-year event free survival (EFS) and overall survival (OS) of the evaluable patients were 70.3±8.3{\%} and 76.8±7.6{\%}, respectively. Extent of tumor necrosis, platelet count at diagnosis, decline in serum alpha fetoprotein, and surgical margin status (positive vs. negative) were statistically significant predictors for both EFS and OS by univariate analysis. Multivariate analyses revealed that extent of tumor necrosis and surgical margin status predicted improved EFS (P<0.001) and OS (P<0.0001). Conclusions: Extent of tumor necrosis following neo-adjuvant chemotherapy is an independent prognostic factor in patients with newly diagnosed HB. Histological response may potentially be used in strategies to modify post-surgical therapy to improve survival in HB.",
keywords = "Alpha-fetoprotein, Chemotherapy, Hepatoblastoma, Necrosis, Platelet count, Surgery",
author = "Rajkumar Venkatramani and Larry Wang and Jemily Malvar and Dennis Dias and Richard Sposto and Marcio Malogolowkin and Leo Mascarenhas",
year = "2012",
month = "9",
day = "1",
doi = "10.1002/pbc.24038",
language = "English (US)",
volume = "59",
pages = "493--498",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma

AU - Venkatramani, Rajkumar

AU - Wang, Larry

AU - Malvar, Jemily

AU - Dias, Dennis

AU - Sposto, Richard

AU - Malogolowkin, Marcio

AU - Mascarenhas, Leo

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Background: Tumor response to chemotherapy has been shown to predict outcome in children with acute lymphoblastic leukemia, osteosarcoma, and Ewing Sarcoma. We evaluated whether tumor necrosis following neo-adjuvant chemotherapy is prognostic for survival in hepatoblastoma (HB). Procedure: Primary tumors from children with newly diagnosed stage III and IV HB who underwent surgical resection following neo-adjuvant chemotherapy were evaluated histologically for the extent of tumor necrosis (total diameter of necrotic and fibrotic tissue divided by total diameter of tumor). Clinical features, laboratory values, pathological features, treatment delivered, and vital status were recorded. Univariate and multivariate Cox regression analyses were performed to evaluate prognostic factors. Results: Thirty-two patients were evaluable. After a median of four cycles of neo-adjuvant chemotherapy gross total surgical resection was achieved in 29 patients and complete resection documented by histology in 22 patients. Three-year event free survival (EFS) and overall survival (OS) of the evaluable patients were 70.3±8.3% and 76.8±7.6%, respectively. Extent of tumor necrosis, platelet count at diagnosis, decline in serum alpha fetoprotein, and surgical margin status (positive vs. negative) were statistically significant predictors for both EFS and OS by univariate analysis. Multivariate analyses revealed that extent of tumor necrosis and surgical margin status predicted improved EFS (P<0.001) and OS (P<0.0001). Conclusions: Extent of tumor necrosis following neo-adjuvant chemotherapy is an independent prognostic factor in patients with newly diagnosed HB. Histological response may potentially be used in strategies to modify post-surgical therapy to improve survival in HB.

AB - Background: Tumor response to chemotherapy has been shown to predict outcome in children with acute lymphoblastic leukemia, osteosarcoma, and Ewing Sarcoma. We evaluated whether tumor necrosis following neo-adjuvant chemotherapy is prognostic for survival in hepatoblastoma (HB). Procedure: Primary tumors from children with newly diagnosed stage III and IV HB who underwent surgical resection following neo-adjuvant chemotherapy were evaluated histologically for the extent of tumor necrosis (total diameter of necrotic and fibrotic tissue divided by total diameter of tumor). Clinical features, laboratory values, pathological features, treatment delivered, and vital status were recorded. Univariate and multivariate Cox regression analyses were performed to evaluate prognostic factors. Results: Thirty-two patients were evaluable. After a median of four cycles of neo-adjuvant chemotherapy gross total surgical resection was achieved in 29 patients and complete resection documented by histology in 22 patients. Three-year event free survival (EFS) and overall survival (OS) of the evaluable patients were 70.3±8.3% and 76.8±7.6%, respectively. Extent of tumor necrosis, platelet count at diagnosis, decline in serum alpha fetoprotein, and surgical margin status (positive vs. negative) were statistically significant predictors for both EFS and OS by univariate analysis. Multivariate analyses revealed that extent of tumor necrosis and surgical margin status predicted improved EFS (P<0.001) and OS (P<0.0001). Conclusions: Extent of tumor necrosis following neo-adjuvant chemotherapy is an independent prognostic factor in patients with newly diagnosed HB. Histological response may potentially be used in strategies to modify post-surgical therapy to improve survival in HB.

KW - Alpha-fetoprotein

KW - Chemotherapy

KW - Hepatoblastoma

KW - Necrosis

KW - Platelet count

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84863872152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863872152&partnerID=8YFLogxK

U2 - 10.1002/pbc.24038

DO - 10.1002/pbc.24038

M3 - Article

VL - 59

SP - 493

EP - 498

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -